Physician profile
John A Renda
NPI 1447227566
$3,732.01
in general payments reported to CMS, 2019-2025
29 companies · $835 in 2025
The $835 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $60.30 · 2021: $331 · 2022: $346 · 2023: $703 · 2024: $913 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,450.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $914.30 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $698.82 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $403.83 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.48 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $165.24 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Idorsia Pharmaceuticals US INC | $144.71 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $132.16 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $112.47 | 2024-2025 | Voquezna |
| Pfizer INC. | $109.53 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $104.49 | 2019-2022 | |
| Abbvie INC. | $101.95 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $83.23 | 2019-2023 | |
| Corcept Therapeutics | $81.93 | 2025 | Korlym |
| Abbott Laboratories | $75.16 | 2021-2023 | Freestyle Libre 3 |
| Eisai INC. | $52.81 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $39.19 | 2019 | |
| Merck Sharp & Dohme LLC | $30.43 | 2019-2024 | Lagevrio, Dificid |
| Amgen INC. | $30.03 | 2021-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $27.56 | 2023-2024 | Rexulti |
| Exact Sciences Corporation | $25.81 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $23.33 | 2019-2020 | |
| Horizon Therapeutics Plc | $23.22 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $14.35 | 2019 | |
| Astellas Pharma US INC | $14.07 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $13.85 | 2021 | |
| Lundbeck LLC | $13.64 | 2021 | |
| Genentech USA, INC. | $13.35 | 2019 | |
| Redhill Biopharma INC. | $12.98 | 2022 | |
| Bausch Health US, LLC | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Renda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.